Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 397-404

  Sellers, Thomas A ^a   Huang, Yifan ^a   Cunningham, Julie ^b   Goode, Ellen L ^b   Sutphen, Rebecca ^a   Vierkant, Robert A ^b   Kelemen, Linda E ^c   Fredericksen, Zachary S ^b   Liebow, Mark ^b   Pankratz, V Shane ^b   Hartmann, Lynn C ^b   Myer, Jeff ^b   Iversen Jr , Edwin S ^d   Schildkraut, Joellen M ^e   Phelan, Catherine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d Duke University   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLYCOSYLATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 39449117328     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0565     Document Type: Article

References (33)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
6. Risch HA, McLaughlin JR, Cole DE, et al. A. Prevalence and penetrance of germline BRCA1 and BRCA2mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
7. Lynch HT, Conway T, Lynch J. Hereditary ovarian cancer. Pedigree studies. Part II. Cancer Genet Cytogenet 1991;53:161-83.
8. Lynch HT, Lemon S, Lynch J, Casey MJ. Hereditary gynecologic cancer. Cancer Treat Res 1998;95:1-102.
9. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114-25.
10. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
11. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2mutations in a large United States sample. J Clin Oncol 2006;24:863-71.
12. Sekine M, Nagata H, Tsuji S, et al. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-25. Hum Mol Genet 2001;10:1421-9.
13. Giuntoli RL, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene expression in ovarian cancers. Cancer Res 1998;58:5546-50.
14. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231.
15. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
16. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125-31.
17. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:30-5.
18. Sellers TA, Schildkraut JM, Pankratz VS, et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2536-43.
19. Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases. Glycobiology 2003;13:1-16R.
20. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
21. Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006;34:W635-41.
22. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2004;2:4.
23. Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 2006;19:1386-94.
24. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-53.
25. Hooper LV, Gordon JI. Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. Glycobiology 2001;11:1-10R.
26. Wandall HH, Hassan H, Mirgorodskaya E, et al. Substrate specificities of three members of the human UDP-N-acetyl-α-D-galactosamine: polypeptide N- acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J Biol Chem 1997;272:23503-14.
27. Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol 1988;128:771-7.
28. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270:2813-8.
29. Pati S, Cullins V. Female sterilization. Evidence. Obstet Gynecol Clin North Am 2000;27:859-99.
30. Whittemore AS, Wu ML, Paffenbarger RS, Jr., et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988;128:1228-40.
31. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933-5.
32. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
33. Wahlberg C. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA 1994;271:1236; author reply 1236-7.